drugset / Trial / NCT04849416

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

NCT04849416

NaSingle-groupOpen-labelTreatment

Summary

A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.

Timeline

Start
2021-05-14
Primary completion
2023-04-10
Completion
2025-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 200 mg Oral